These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 18779739)

  • 21. Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
    Goldstein JL; Scheiman JM; Fort JG; Whellan DJ
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):121-6. PubMed ID: 27002280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.
    Kelly JP; Kaufman DW; Jurgelon JM; Sheehan J; Koff RS; Shapiro S
    Lancet; 1996 Nov; 348(9039):1413-6. PubMed ID: 8937281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proximal predominance of small bowel injury associated with uncoated low-dose aspirin therapy: a video capsule study in chronic users.
    Ehrhard F; Nazeyrollas P; Brixi H; Heurgue-Berlot A; Thiéfin G
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1265-72. PubMed ID: 23873021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of gastroduodenal erosions in patients taking low-dose aspirin.
    Hart J; Hawkey CJ; Lanas A; Naesdal J; Talley NJ; Thomson AB; Yeomans ND
    Aliment Pharmacol Ther; 2010 Jan; 31(1):143-9. PubMed ID: 19709095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study.
    Watanabe T; Sugimori S; Kameda N; Machida H; Okazaki H; Tanigawa T; Watanabe K; Tominaga K; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1279-82. PubMed ID: 18995219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salicylsalicylic acid causes less gastroduodenal mucosal damage than enteric-coated aspirin. An endoscopic comparison.
    Scheiman JM; Behler EM; Berardi RR; Elta GH
    Dig Dis Sci; 1989 Feb; 34(2):229-32. PubMed ID: 2914543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term/low-dose aspirin-induced duodenal erosions are not dependent on Helicobacter pylori infection, cyclooxygenase expression and prostaglandin E2 levels.
    Venerito M; Treiber G; Wex T; Kuester D; Roessner A; Mönkemüller K; Malfertheiner P
    Scand J Gastroenterol; 2008; 43(7):801-9. PubMed ID: 18584518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo controlled endoscopic study of a new enteric-coated formulation versus regular formulation in healthy volunteers.
    Blondon H; Barbier JP; Mahé I; Deverly A; Kolsky H; Bergmann JF
    Fundam Clin Pharmacol; 2000; 14(2):155-7. PubMed ID: 10796063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study.
    Fiorucci S; Santucci L; Gresele P; Faccino RM; Del Soldato P; Morelli A
    Gastroenterology; 2003 Mar; 124(3):600-7. PubMed ID: 12612897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between serum triglycerides and gastro-duodenal ulcer associated with low-dose aspirin.
    Fujii T; Nakabayashi T; Hashimoto S; Kuwano H
    Hepatogastroenterology; 2009; 56(93):1241-4. PubMed ID: 19760979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimization of gastric damage with enteric-coated aspirin granules compared to buffered aspirin.
    Anslow JA; Balm TK; Hooper JW; Szego P; Wagner GS
    Pharmacology; 1985; 30(1):40-4. PubMed ID: 3975255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?
    Laine L
    Aliment Pharmacol Ther; 2006 Sep; 24(6):897-908. PubMed ID: 16948802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs, gastritis, and peptic ulcer.
    Ivey KJ
    J Clin Gastroenterol; 1981; 3(Suppl 2):29-34. PubMed ID: 7320467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin.
    Graham DY; Malaty HM; Goodgame R
    Am J Gastroenterol; 1997 Aug; 92(8):1322-5. PubMed ID: 9260798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study.
    Tamura A; Murakami K; Kadota J;
    QJM; 2011 Feb; 104(2):133-9. PubMed ID: 20870780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoscopic aspects of gastroduodenal mucosa due to NSAIDs.
    Ruina M; Caselli M; Sartori S; Trevisani L; La Corte R; Trotta F; Alvisi V
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():9-11. PubMed ID: 9032574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastroduodenal mucosal damage with salsalate versus aspirin: results of experimental models and endoscopic studies in humans.
    Scheiman JM; Elta GH
    Semin Arthritis Rheum; 1990 Oct; 20(2):121-7. PubMed ID: 2123561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa.
    Hoftiezer JW; O'Laughlin JC; Ivey KJ
    Gut; 1982 Aug; 23(8):692-7. PubMed ID: 7095565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man.
    Hoftiezer JW; Silvoso GR; Burks M; Ivey KJ
    Lancet; 1980 Sep; 2(8195 pt 1):609-12. PubMed ID: 6107406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.